Meditera Tibbi Malzeme Sanayi ve Ticaret AS Capital Reinvestment Ratio
Meditera Tibbi Malzeme Sanayi ve Ticaret AS capital reinvestment ratio. Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has a Capital Reinvestment Ratio of 0.13x as of March 2026, meaning it reinvests 0% of its operating cash flow (TL180.45 Million) in capital expenditures (TL24.08 Million). Check how aggressively does Meditera Tibbi Malzeme Sanayi ve Ticaret reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2020–2025)
Capital reinvestment ratio of Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2020 to 2025. This chart tracks Meditera Tibbi Malzeme Sanayi ve Ticaret AS's Capital Reinvestment Ratio across 6 annual periods. Also explore Meditera Tibbi Malzeme Sanayi ve Ticaret (MEDTR) equity growth momentum to track the company's year-over-year net asset growth rate.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Capital Reinvestment Ratio by Year (2020–2025)
Meditera Tibbi Malzeme Sanayi ve Ticaret AS capital reinvestment ratio by year from 2020 to 2025. For the full cash flow conversion analysis, see MEDTR operating cash flow.
| Year | Reinvestment Ratio | Operating CF (TRY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.44x | TL435.35 Million | TL191.67 Million | ▲ +30.4% |
| 2024 | 0.34x | TL780.69 Million | TL263.52 Million | ▼ -9.8% |
| 2023 | 0.37x | TL801.02 Million | TL299.70 Million | ▼ -96.3% |
| 2022 | 10.07x | TL5.10 Million | TL51.35 Million | ▲ +4036.4% |
| 2021 | 0.24x | TL36.64 Million | TL8.92 Million | ▼ -14.5% |
| 2020 | 0.28x | TL73.26 Million | TL20.85 Million | — |